Intermediate-risk AML is a group of heterogeneous disease, complete and accurate understanding of their molecular pattern are urgent. We 
Introduction
Cytogenetic lesions is used as diagnostic and prognostic markers and also to elucidate the molecular pathogenesis of acute myeloid leukemia (AML) for more than three decades (Mrozek et al. 2004; Rowley 2008 ).
However, nearly half of the AML patients don't have apparent cytogenetic structural abnormalities, they are intermediate-cytogenetic risk (Martelli et al. 2013 ). However, their clinical outcomes are greatly heterogeneous and lacks effective prognostic indicators at the same time. Some of these patients respond well to chemotherapy, while others not. Therefore, recent studies have focused on improving classification of intermediate-risk AML patients. Mutations, aberrantly expressed genes, microRNAs and changes in DNA methylation are potential prognostic markers. For example, mutations of CEBPA and NPM1 are associated with favorable outcomes (Ahn et al. 2016; Han et al. 2013; Li et al. 2015) , whereas mutations of FLT3-ITD, WT1, MLL, TET2 and DNMT3A are associated with an unfavorable clinical outcome (Ley et al. 2010; Mikulasova et al. 2010; Ribeiro et al. 2012; Stirewalt & Radich 2003) . High expression of WT1, ERG, and DNMT3B as well as low expression of LEF1 have also been shown to be unfavorable prognostic factor (Metzeler et al. 2009; Metzeler et al. 2012; Schulze et al. 2016; Yi-Ning et al. 2015) . However, none of the present classification strategies conform to clinical needs entirely, which suggests that a more complete and accurate understanding of the genetic 
RNA Sequencing analyses
Gene expression data have been previously published. Briefly, gene expression data were obtained using RNA Sequencing. All the design and quality control for this experiment were based on the standard protocols.
Patients with OS and EFS values above the median of all patients were subdivided into the OS longer and EFS longer group while others were into OS shorter and EFS shorter group. Gene expression levels were also determined from the normalized data.
Statistical analyses
The time from date of diagnosis to removal from study due to absence of complete remission, relapse or death defined EFS, and the time from date of diagnosis to death due to any cause defined OS. Firstly, we classified the 98 AML patients into two groups based on OS and EFS value respectively. Log-rank Test was used to estimate the association between gene expressions and EFS and OS of the patients, which were further validated using Gehan-Breslow-Wilcoxon test. Student's t-test and multiple hypothesis correction (False Discovery Rate, FDR) was used to identify differences in gene expression profiles. The statistical cutoff values were a fold-change (FC) ≥1.5 and an adjusted P-value < 0.05. All analyses were performed using the R3.2.2 software packages and GraphPad Prism 5.0.
Results

Clinical characteristics of primary intermediate-risk AML patients
In months, while median EFS was 9.4(0-100.5) months (Table 1) . Table S1 and S2). The overlaps were six genes including SPANXC, ADAMTS15, C8B, FAM183A, FLJ42875 and PXDN (Figure 2 ).
No strong association among them was found. 
Expression of differential genes in AML samples
Next, we analyzed the RNA Sequencing data to obtain the expression of six differential genes mentioned above in intermediate-risk AML patients. As indicated in the Figure 2 We performed the survival analysis based on the expression of two widely expressed genes, FLJ42875 and PXDN. Firstly, we subdivided 98 AML patients into four quartiles (Q1: <25%, Q2: 25~50%, Q3: 50~75%, Q4: >75%) based on their expression value. The survival curves showed that PXDN Q1 expression was associated significantly shortened OS and EFS (P=0.0001, P=0.0032, respectively; Figure 3A and Figure 3B ).
Relationship between genes' expression and survival in primary intermediate-risk AML patients
However, OS and EFS of FLJ42875 Q2 expression group were significantly prolonged than others (P=0.0157, P=0.0074, respectively; Figure 3C and Figure 3D ), the difference was still significant by revalidation of Gehan-Breslow-Wilcoxon test. After adjusting for the impact of several known risk factors, we performed multivariable analyses to determine the prognostic significance of FLJ42875 and PXDN expression. In the multivariable model of OS, PXDN Q1 group had a shorter OS (P < 0.001, Table 2 ). The other factors associated with shorter OS was age more than or equal to 60 years old. While in the multivariable model of EFS, PXDN Q1 group had a shorter EFS (P =0.009, Table 2 ).
FLJ42875 Q2 group had a prolonged OS and EFS (P=0.050, P=0.023; respectively). PXDN, a member of the larger peroxidase gene family, is an adhesion molecule involved in ECM formation (Peterfi et al. 2014; Tauber et al. 2010) . It is one of the target genes of miR-29a. Ectopic overexpression of miR-29a promoted self-renewal of myeloid progenitors and led to AML ultimately in mouse model (Oliveira et al. 2015 ). What's more, PXDN were diminished in AML (Desmond et al. 2007 Researches on FLJ42875 were limited. Only in a case report, upregulation of FLJ42875 by t(1;2)(p36;p21) translocation during evolution of CMML was reported with no further insight into mechanism of this gene (Storlazzi et al. 2008) . 
